2 of 2 parts

Study: BP medicine linked to lower COVID-19 death risk in hypertension patients

By: Team Ifairer | Posted: 08-06-2020
Heart It
Study: BP medicine linked to lower COVID-19 death risk in hypertension patients
Study: BP medicine linked to lower COVID-19 death risk in hypertension patients
, study,  bp medicine linked to lower covid-19 death risk in hypertension patients,  bp medicine,  covid-19,  hypertension,  coronavirus,  research,  ifairer
These drugs, they said, included angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs). The scientists also assessed the performance of other, non-RAAS inhibiting drugs used for treating high blood pressure such as beta blockers, calcium channel blockers (CCBs), or diuretics. In their analysis, the researchers found a lower risk of death among the 183 patients treated with RAAS inhibitors than in 527 patients treated with other drugs.

However, the scientists say this result should be treated with caution as the number of patients in this analysis was small, and so it could be due to chance."It is important that patients with high blood pressure realise that they are at increased risk of dying from COVID-19," Li said.

"They should take good care of themselves during this pandemic and they need more attention if they are infected with the coronavirus," he added. In addition, the scientists noted that there were 140 patients admitted to hospital with COVID-19 who had discontinued their anti-hypertensive treatment due to various reasons.

"We found that this was associated with a greater risk of dying from the coronavirus," Li said. "In contrast to our initial hypothesis, we found that RAAS inhibitors, such as ACE inhibitors or angiotensin receptor blockers, were not linked to an increased risk of dying from COVID-19 and, in fact, may be protective," the scientists said. They suggested that patients should not discontinue or change their usual antihypertensive treatment unless instructed by a physician.

Since the assessed study looked at data from observations in the hospital, and was not based on a randomised controlled clinical trial, the researchers said it is too early to make clinical recommendations based on these results. "These data should be interpreted cautiously. However, they support recommendations for the European Society of Cardiology that patients should not discontinue or change their normal, antihypertensive treatment," Tao said.
Study: BP medicine linked to lower COVID-19 death risk in hypertension patients
Previous
Tags :
study, bp medicine linked to lower covid-19 death risk in hypertension patients, bp medicine, covid-19, hypertension, coronavirus, research, ifairer

Dare To Share